The HFC has developed a score integrating classes and doses of guideline-directed medical therapies prescribed for patients with heart failure (HF) and reduced ejection fraction. One potential use of this score is to test whether new treatments demonstrate incremental benefits, even in patients receiving comprehensive guideline-directed medical therapy.

Editors

Editor-in-Chief
Christopher O’Connor, MD, FACC

Executive Editor
Mona Fiuzat, PharmD, FACC

JACC Heart Failure CME Editors
Tariq Ahmad, MD, MPH
Adam DeVore, MD
Abhinav Sharma, MD
Mitchell Psotka, MD, PhD
Kishan Parikh, MD

Author
Brent C. Lampert, MD 

Important Dates

Date of Release: July 25, 2022
Term of Approval/Date of CME/MOC/ECME Expiration: July 24, 2023